Kamran Alam
2022 - Taysha Gene Therapies
In 2022, Kamran Alam earned a total compensation of $1.2M as Chief Financial Officer at Taysha Gene Therapies, a 34% decrease compared to previous year.
Compensation breakdown
| Bonus | $156,000 |
|---|---|
| Non-Equity Incentive Plan | $136,578 |
| Option Awards | $498,215 |
| Salary | $401,700 |
| Other | $9,330 |
| Total | $1,201,823 |
Alam received $498.2K in option awards, accounting for 41% of the total pay in 2022.
Alam also received $156K in bonus, $136.6K in non-equity incentive plan, $401.7K in salary and $9.3K in other compensation.
Rankings
In 2022, Kamran Alam's compensation ranked 2,653rd out of 5,625 executives tracked by ExecPay. In other words, Alam earned more than 52.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,653 out of 5,625 | 53rd |
Division Manufacturing | 1,471 out of 3,053 | 52nd |
Major group Chemicals And Allied Products | 673 out of 1,380 | 51st |
Industry group Drugs | 626 out of 1,281 | 51st |
Industry Biological Products, Except Diagnostic Substances | 157 out of 295 | 47th |
Source: SEC filing on May 8, 2023.
Alam's colleagues
We found three more compensation records of executives who worked with Kamran Alam at Taysha Gene Therapies in 2022.
News
Taysha Gene Therapies CEO Sean Nolan's 2023 pay slips 20% to $1.5M
April 18, 2024
Taysha Gene Therapies CEO RA Session's 2022 pay falls 57% to $2M
May 8, 2023
Taysha Gene Therapies CEO RA Session's 2021 pay slips 3% to $4.6M
April 28, 2022
Inotek Pharmaceuticals CEO Gaurav Shah's 2019 pay falls 39% to $3.9M
April 24, 2020
Aquinox Pharmaceuticals CEO Jonathan Drachman receives $3.8M in 2019
March 24, 2020
Aquinox Pharmaceuticals CEO David Main's 2018 pay jumps 39% to $4.2M
October 2, 2019